ACXP Rasio cepet Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals (ACXP) is developing innovative antibiotics to combat resistant superbugs, leveraging support from the CDC and the success of irezamicin. This price chart with the 4.00 indicator illustrates the price action of an asset whose potential depends on future drug supplies to the hospital sector. The company is currently in a pre-commercial phase, utilizing its existing capital to complete the necessary research.

Acurx Pharmaceuticals (ACXP) attracts top microbiology specialists through an RSU system and an academic culture. Analyzing the recorded quick liquidity ratio on GURU.Markets, an investor can see the company's ability to meet its obligations using cash and accounts receivable. This indicator excludes illiquid inventories, revealing real financial stability without accounting for goods. High values confirm reliability but may indicate inefficient capital allocation.